NuScale Power Innovates With Integrated Systems for Clean Water, Hydrogen Production
NuScale's research indicates that a single NuScale Power Module/NPM paired with a state-of-the-art reverse osmosis desalination system could produce ~150 million gallons of clean water daily, without generating carbon dioxide. Furthermore, a plant with 12 NPMs would be capable of providing desalinated water for a city of 2.3 million residents while also generating surplus power to electrify 400,000 homes.
A Nuclear power plant with all its safety & security protocols in place.
To tackle the environmental challenge posed by brine, which is a byproduct of the desalination process, NuScale's research team has developed a novel approach for hydrogen storage, transport, and production that utilizes this leftover brine as an industrial feedstock. NuScale collaborated with experts at the US Department of Energy's Pacific Northwest National Laboratory to investigate hydrogen production from an inert salt derived from water desalination byproducts.
NuScale's hydro-thermal chemical decomposition method for hydrogen production eliminates the need for water electrolysis, thereby reducing energy and water consumption and lowering costs. The process is carbon-free if powered by NuScale's integrated energy systems. The research on this innovative approach was presented at the World Petrochemical Conference in March 2025.
NuScale Power Corporation (NYSE:SMR) provides small modular reactor technology solutions. It offers NuScale Power Module, which is a water reactor that can generate 77 megawatts of electricity.
While we acknowledge the potential of SMR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the .
READ NEXT: and .
Disclosure: None. This article is originally published at Insider Monkey.
Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade
Key Points UnitedHealth Group's reduced profit forecast for 2025 is disappointing, but the health insurance business is in a good position to bounce back. Coca-Cola's dividend payout has risen for 63 consecutive years. Amgen sells over a dozen drugs that are growing sales at a double-digit annual percentage. 10 stocks we like better than UnitedHealth Group › Income-seeking investors who value their time know the best dividend stocks don't need a lot of babysitting. Some go on decades-long payout-raising streaks. The Dow Jones Industrial Average (DJINDICES: ^DJI) is one of the best places to find reliable dividend payers. Stocks aren't added to this exclusive list unless they have already demonstrated an ability to produce profits in good economic times and bad ones, too. The average dividend payer in the Dow Jones Industrial Average offers a measly 1.6% yield at recent prices. UnitedHealth Group (NYSE: UNH), Coca-Cola (NYSE: KO), and Amgen (NASDAQ: AMGN) stand out with above-average yields. Here's why they could be great additions to a long-term dividend investor's portfolio. 1. UnitedHealth Group Shares of UnitedHealth Group collapsed in May, after the company simultaneously suspended its 2025 outlook and announced an abrupt CEO exit. To top it off, the company felt it was necessary to issue responses to several Wall Street Journal articles and a Department of Justice investigation regarding its Medicare business. The stock is down, but its dividend payout is way up. The company raised it by 76.8% over the past five years. At its beaten-down price, the stock offers a 2.7% yield. Health insurance businesses operate on thin margins. It turns out that UnitedHealth mispriced premiums going into 2025. Healthcare providers are charging more than the company anticipated, plus the amount of care new members have been using is also higher than expected. Smart investors such as Warren Buffett know that UnitedHealth Group is mostly a middleman that can pass increased costs on to health plan sponsors. It may have mispriced premiums going into 2025, but this isn't a mistake its recently refreshed management team is likely to make again in the decade ahead. 2. Coca-Cola Unlike UnitedHealth, Coca-Cola stock is up near its all-time high. The soda giant's dividend hasn't risen as sharply as the health insurer's, but it's still up by 24.4% over the past five years. Being the only company that can sell many of the world's most popular beverage brands is a strong advantage that leads to consistent profits. In February, the company announced a dividend raise for the 63rd year in a row. Shares of Coca-Cola offer a 2.9% yield at recent prices, and another decade of significant dividend raises isn't an unreasonable expectation. Second-quarter unit case volume fell by 1%, but the strength of its brands allowed organic revenue to rise by 5% year over year. Sales of sugary sodas have been losing ground to sports drinks, but the company has this base covered. Its BodyArmor brand boasts a double-digit share of the U.S. market, and its older Powerade brand is even more popular. Adding some shares of this stock to a diverse portfolio is an almost certain way to boost your passive income stream over time. 3. Amgen Shares of biotechnology pioneer Amgen have been trading about 12% below the all-time high they set last year. Amgen began paying a dividend in 2011 and has been able to increase it every year since. The drugmaker raised its payout by 48.8% over the past five years. At recent prices, it offers a 3.2% yield. Two of Amgen's top revenue streams, Enbrel and Prolia, are drying up thanks to biosimilar competition. Fortunately, the losses are easily offset by a slew of more recently launched products. Amgen recently reported year-over-year sales increases at a double-digit percentage for 15 products in the second quarter. New competition for Enbrel and Prolia limited second-quarter sales growth to 9% year over year. Enbrel and Prolia losses will most likely reach a bottom long before Amgen's new growth drivers run out of fuel. With a strong lineup of new products, this company could report strong sales growth in the decade ahead. Should you buy stock in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. 3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Combination Cancer Therapies Surge: The Young Adult Treatment Revolution
As cancer rates climb 30% among adults under 50, combination immunotherapy companies are advancing breakthrough treatments and institutional investors are committing $243.62 billion to capture the rapidly expanding precision oncology market. A medical crisis is reshaping the cancer treatment landscape. Young adults under 50 are experiencing unprecedented cancer rates, with aggressive tumors requiring innovative combination approaches that go far beyond traditional single-drug therapies. According to Memorial Sloan Kettering Cancer Center, cancer incidence rates in women under 50 are now 82% higher than their male counterparts, up from 51% in 2002. The American Cancer Society reports that colorectal cancer has become the leading cause of cancer deaths among young men and the second leading cause among young women, fundamentally changing treatment priorities across the oncology spectrum. The market response reflects this urgency. Mordor Intelligence projects the global cancer therapy market will surge from $243.62 billion in 2025 to $403.99 billion by 2030, reflecting a 10.64% CAGR driven by demand for combination therapies specifically designed to combat the more aggressive cancers plaguing younger demographics. Keep reading to discover how combination immunotherapy approaches are revolutionizing treatment for young adult cancer patients and which companies are positioned to dominate this rapidly evolving market. For a detailed analysis of one company leading this transformation, click here. Leading Companies in the Combination Therapy Revolution Combination immunotherapy is attracting significant institutional investment, with these companies making strategic moves: AstraZeneca PLC (NASDAQ: AZN) --- AstraZeneca recently received FDA Priority Review and Breakthrough Therapy Designation for its Imfinzi immunotherapy in early-stage gastric cancers, with FDA decision anticipated in Q4 2025. The perioperative combination regimen showed a 29% reduction in disease progression risk, positioning the company to capture significant market share as gastric cancers increasingly affect younger populations with more aggressive disease patterns. Bristol Myers Squibb Company (NYSE: BMY) --- Bristol Myers Squibb recently secured FDA approval for its Opdivo-Yervoy combination as first-line treatment for unresectable liver cancer, converting a previous accelerated approval. The dual checkpoint inhibitor regimen directly competes with rival immunotherapy combinations and offers potential for longer survival compared to traditional targeted therapies, particularly relevant as liver cancers show rising incidence in younger adults. Amgen Inc. (NASDAQ: AMGN) --- Amgen recently gained FDA approval for Imdelltra, its breakthrough bispecific T-cell engager for extensive-stage small-cell lung cancer, with pricing at $31,500 per first cycle. The drug demonstrated a tripling of survival duration to 14.3 months median overall survival in a disease where median survival typically reaches only 5 months, addressing the urgent need for effective treatments in the deadliest form of lung cancer. Pfizer Inc. (NYSE: PFE) --- Pfizer recently showcased breakthrough data across its oncology portfolio at ASCO 2025, featuring combination approaches in breast, genitourinary, and thoracic cancers. The company's Braftovi combination doubled survival time for patients with aggressive colorectal cancer in late-stage trials, representing significant progress for a cancer type that disproportionately affects younger adults with traditionally poor prognosis and limited treatment options. The $403.99 Billion Combination Therapy Opportunity The convergence of rising young adult cancer rates and breakthrough combination immunotherapies is creating unprecedented market expansion across every segment of oncology treatment. Read: Mining Stocks Finally Wake Up as Gold Stays Hot Above $3,300 $40 Silver Breakout Imminent as Miners Enter High-Momentum Phase Encryption Is Dying—Here's What Comes Next for Cyber Defense FDA Fast-Track Cancer Treatments Drive $900B Market Growth Forecast Mining Stocks Outpace Gold's Historic Rally as Sector Primes for Breakout According to Mordor Intelligence, the global cancer therapy market will reach $403.99 billion by 2030, with combination immunotherapies representing the fastest-growing segment. The shift toward treating younger patients with more aggressive cancers requiring multi-drug approaches is fundamentally altering treatment economics and creating new revenue opportunities for companies developing sophisticated combination regimens. Precedence Research forecasts the cancer therapeutics market will expand from $194.67 billion in 2024 to $469.38 billion by 2034, representing a 9.20% CAGR. This explosive growth is being driven by the unique challenges of treating younger patients whose cancers often resist single-agent therapies and require novel combinations of checkpoint inhibitors, targeted therapies, and next-generation immunomodulators specifically designed for aggressive tumor biology. Global Market Insights projects the oncology market will reach $866.1 billion by 2034, growing at a 10.8% CAGR. The market expansion is being accelerated by the urgent need to address the 30% surge in young adult cancer cases projected through 2030, with combination therapies representing the most promising approach to combat the treatment-resistant, aggressive cancers increasingly diagnosed in this demographic. The Bottom Line The combination therapy revolution is accelerating rapidly, driven by the unprecedented cancer epidemic affecting young adults who require more sophisticated treatment approaches than traditional single-drug regimens can provide. With aggressive cancers becoming more prevalent in younger demographics, the demand for innovative combination immunotherapies is creating massive market opportunities. Institutional investors are positioning for explosive growth as companies develop next-generation combination platforms specifically designed to address the unique molecular characteristics and treatment resistance patterns exhibited by cancers in younger patients. While the companies mentioned represent established leaders in combination therapy development, one innovative biotech has quietly advanced a viral immunotherapy platform that combines multiple mechanisms of action in a single treatment approach. To learn more about this emerging opportunity, click here.
Yahoo
an hour ago
- Yahoo
3 Cheap Stocks Under $100 That Look Like Absolute Steals Right Now
Key Points Pinterest, United Parcel Service, and Comcast are some of the cheapest big-name stocks you can buy right now. They all trade at low earnings multiples and can be strong long-term investments. 10 stocks we like better than Pinterest › If you don't want to chase all-time highs and buy stocks at extremely high valuations, the good news is that there are many decently priced options. And below, I'm going to focus on what I think are some of the best deals available. Three stocks that trade at less than $100 per share and can be bargain buys right now include Pinterest (NYSE: PINS), United Parcel Service (NYSE: UPS), and Comcast (NASDAQ: CMCSA). A couple are facing concerning headwinds, but here's why they can all be great long-term investments. Pinterest Pinterest is a popular social media site where people go for ideas related to just about anything. Whether it's home renovation projects, baking, or recent shopping hauls, there's a ton of content to sift through. The platform is particularly popular with Gen Z, which Pinterest says accounts for more than 40% of its monthly user base. Entering this week, shares of Pinterest have been trading around $35, and that's with the stock rising 24% since the start of the year. And yet, it's still a cheap buy, trading at just 13 times its trailing earnings. Its price/earnings-to-growth multiple, or PEG, is around 0.8. That's based on analyst expectations over the next five years, and it implies that Pinterest is one heck of a cheap growth stock. The company's top line rose by 17% in its most recent quarter (which ended on June 30), to just under $1 billion. Monthly active users rose by 11% to 578 million. With a market cap of only $24 billion, Pinterest is a business that could get a whole lot more valuable given how popular it is with younger audiences. It can be a terrific long-term buy. United Parcel Service There's not much growth happening for United Parcel Service these days. The logistics company is battling significant macroeconomic headwinds due to tariffs. It's trading at less than $90, and the last time you could have bought the stock at a much cheaper price than that was in 2013. UPS is facing some near-term challenges, but it's hard to not like the business over the long haul. The world of e-commerce is still getting bigger, and demand for global shipments isn't likely to slow down. There may be short-term adversity, but if you're a long-term investor, you don't need to worry too much about UPS given its dominance in the industry. The company is making tough but smart decisions, such as scaling back on volume from Amazon in an effort to improve profitability. And it is profitability, not simply sales, that should drive decisions. Although it may not be a popular move and it may hurt the top line, if it improves profit margins, that could be a big win in the end. UPS is trading at a price-to-earnings multiple (P/E) of 13, and in the long run it could have plenty of upside as economic conditions improve. Comcast Rounding out this list of cheap stocks is media and tech company Comcast. It's trading around $34, and its P/E is less than 6 -- an astoundingly low valuation for one of the largest entertainment companies in the country. Its high debt load (around $100 billion) is undoubtedly turning away a lot of risk-averse investors. But with Comcast spinning off many cable TV networks later this year, that could help reduce costs and allow it to focus on higher-growth opportunities in areas such as streaming. The business may have become too bloated, and simplifying its approach could work well for investors. Overall, Comcast still has excellent brands in its portfolio, and it's highly profitable, with an operating margin of around 20% over the past six months. I'm optimistic that by becoming leaner, the business can be better positioned for growth in the future. At such a cheap valuation, it may be too tempting to pass up since it offers an excellent margin of safety. Do the experts think Pinterest is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Pinterest make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,077% vs. just 185% for the S&P — that is beating the market by 892.55%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Pinterest, and United Parcel Service. The Motley Fool recommends Comcast. The Motley Fool has a disclosure policy. 3 Cheap Stocks Under $100 That Look Like Absolute Steals Right Now was originally published by The Motley Fool Sign in to access your portfolio
